Mark Cuban’s Cost Plus Drug Company adds new SGLT2 inhibitor Brenzavvy for type 2 diabetes

Mark Cuban’s Cost Plus Drug Com­pa­ny is bring­ing an­oth­er brand-name type 2 di­a­betes treat­ment un­der its wing.

Ther­a­cos­Bio’s re­cent­ly ap­proved SGLT2 in­hibitor Bren­zavvy is now avail­able by pre­scrip­tion through Cuban’s Cost Plus Drugs at $47.85 for a 30-day sup­ply, the drug­mak­er an­nounced Thurs­day.

“We’ve al­ways want­ed to be able to bring this for­ward on an af­ford­able ba­sis to the type 2 di­a­bet­ic pa­tient pop­u­la­tion,” Ther­a­cos­Bio CEO Al­bert Collinson told End­points News. “The sim­ple fact is most peo­ple don’t get ac­cess to new med­ica­tions be­cause their health in­sur­ance makes it dif­fi­cult or it’s as­so­ci­at­ed with sig­nif­i­cant ex­pense.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN